Last reviewed 2026-04-19 · How we verify

Rosuvastatin and GDC-0853

Genentech, Inc. · Phase 1 active Small molecule

Rosuvastatin and GDC-0853 is a Small molecule drug developed by Genentech, Inc.. It is currently in Phase 1 development.

At a glance

Generic name	Rosuvastatin and GDC-0853
Sponsor	Genentech, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rosuvastatin and GDC-0853 CI brief — competitive landscape report
Rosuvastatin and GDC-0853 updates RSS · CI watch RSS
Genentech, Inc. portfolio CI

Frequently asked questions about Rosuvastatin and GDC-0853

What is Rosuvastatin and GDC-0853?

Rosuvastatin and GDC-0853 is a Small molecule drug developed by Genentech, Inc..

Who makes Rosuvastatin and GDC-0853?

Rosuvastatin and GDC-0853 is developed by Genentech, Inc. (see full Genentech, Inc. pipeline at /company/genentech-inc).

What development phase is Rosuvastatin and GDC-0853 in?

Rosuvastatin and GDC-0853 is in Phase 1.

Manufacturer: Genentech, Inc. — full pipeline
Compare: Rosuvastatin and GDC-0853 vs similar drugs
Pricing: Rosuvastatin and GDC-0853 cost, discount & access